CASTLE ROCK, Colo., April 02, 2026 (GLOBE NEWSWIRE) — Riot Platforms, Inc. (NASDAQ: RIOT) (“Riot” or “the Company”), a Bitcoin-driven industry leader in the development of large-scale data centers and bitcoin mining applications, announces unaudited production and operations updates for the first quarter of 2026.   Bitcoin Production and Operations Updates for Q1 2026        Comparison (%)Metric   Q1 2026 1 Q1 2025 1 Quarter/QuarterBitcoin Produced   1,473 1,530 -4%Average Bitcoin Produced per Day   16.4 17.0 -4%Bitcoin Held 2   15,680 3 19,223 -18%Bitcoin Sold   3,778 – N/ABitcoin Sales – Net Proceeds   $289.5 million – N/AAverage Net Price per Bitcoin Sold   $76,626 N/A N/ADeployed Hash Rate – Total 2   42.5 E+H/s 33.7 E+H/s 26%Avg. Operating Hash Rate – Total 4   36.4...

Dublin, April 02, 2026 (GLOBE NEWSWIRE) — Fusion Fuel Green PLC (Nasdaq: HTOO) (“Fusion Fuel” or the “Company”), a leading provider of full-service energy engineering, advisory, and utility solutions, today highlighted certain fiscal year 2025 financial results of its majority-owned subsidiary, Quality Industrial Corp. (OTCID: QIND) (“QIND”), and provided an update on QIND’s business progress. QIND Fiscal Year 2025 Financial Results Highlights For the fiscal year ended December 31, 2025, QIND reported:Revenue of approximately $16.3 million, an increase of 45.9% compared to approximately $11.2 million in fiscal year 2024; Gross profit of approximately $4.8 million, compared to approximately $4.0 million in the prior year, representing a 20.8% increase year-over-year; and Non-GAAP adjusted net income of $564,465,...

MIAMI BEACH, Fla., April 02, 2026 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the fourth quarter and twelve months ended December 31, 2025. Yogi Jashnani, Chief Executive Officer, stated: “In the fourth quarter, we delivered sequential improvement in same store sales versus the first nine months of the year and adjusted EBITDA ahead of the prior year period,” stated Yogi Jashnani, Chief Executive Officer. “During 2025, we took significant steps to enhance our business approach and team. We added talent, improved business processes, implemented a new go-to-market strategy, and added new procedures that expanded our market potential.” “The results of this work are already evident,” continued...

Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026 Timeline for submission of NDA dossier of deucrictibant IR for on-demand treatment of HAE attacks remains on-track in 1H2026 Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks Cash and cash equivalents of €292 million as of December 31, 2025ZUG, Switzerland, April 02, 2026 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced...

Strong Execution Delivers Sales Growth, Margin Expansion and EPS ImprovementDelivered Net Sales of $1.1B, an Increase of 5% Compared to the Prior Year Delivered Operating Profit of $133M, Up 21% Compared to the Prior Year; Grew Adjusted Operating Profit to $176M, Up 8% Compared to the Prior Year Delivered Diluted EPS of $3.09, Up 26% Compared to the Prior Year; Grew Adjusted Diluted EPS to $4.14, Up 11% Compared to the Prior YearATLANTA, April 02, 2026 (GLOBE NEWSWIRE) — Acuity Inc. (NYSE: AYI), (“Acuity”), a market-leading industrial technology company, delivered net sales of $1.1 billion in the second quarter, ended February 28, 2026, an increase of $49.4 million, or 4.9 percent, compared to the prior year. “We demonstrated strong execution in our second quarter of fiscal 2026,” stated Neil Ashe, Chairman,...

Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. The Annual Report is available at annualreport.pharming.com and under Investors/Financial documents on the Pharming.com website. The Company also announced the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC). The 2025 Annual Report on Form 20-F can be found under Investors/SEC filings on Pharming.com and through the SEC website once it has been filed. About Pharming Group N.V. Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases....

Annual Production for 2025 of 50,238 Gold Equivalent Ounces (“GEO”); and AISC of US$1,746 per ounce, in line with guidance 2026 Production guidance of 50,000 to 60,000 GEO weighted to H2/26 Adjusted EBITDA of $22.3 million for Q4, and $46.1 million for the full year Completed hedging program provides full future leverage to high gold prices Exited the year with a strong cash position of over $22 million Management to host Conference Call to discuss the financial and operational results on [April 2nd, 2025, at 11:00 AM EDT]TORONTO, April 02, 2026 (GLOBE NEWSWIRE) — Cerrado Gold Inc. [TSX.V:CERT][OTCQX:CRDOF; FRA:BAI0] (“Cerrado” or the “Company”) announces its operational and financial results for the fourth quarter (“Q4/25”), including its Minera Don Nicolas (“MDN”) gold project in Santa Cruz Province, Argentina, the highly...

EAGAN, Minn., April 01, 2026 (GLOBE NEWSWIRE) — Today the Blue Cross and Blue Shield of Minnesota family of companies (Blue Cross) reported a combined $353 million in operating losses on $10.4 billion in fully insured premium revenue for 2025. This represents an operating margin loss of approximately 3 percent. The reported operating loss includes a premium deficiency reserve of $150 million to cover continued claims expenses that exceed forecasted premium revenue. Strong investment portfolio performance resulted in Blue Cross closing out the year with a positive net income of $83 million. Overall, Blue Cross paid $9.8 billion for members’ medical and pharmacy services in 2025, or nearly $27 million in claims on a daily basis. This represents an increase of $1.7 billion in claims spending over the year prior. Unfavorable performance...

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) — XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), a leading provider of wellness solutions for people on the go, today announced financial results for the year ended December 31, 2025. Recent Operating HighlightsXWELL delivered 2025 revenue of approximately $29.2 million. Total operating expenses decreased by approximately 10% versus the comparable prior year period. Cost of sales decreased approximately 13% versus 2024.   General and administrative expenses decreased approximately 20% year-over-year. In December 2025, the Company opened a new wellness retail location in New York City’s Pennsylvania Station. In February 2026, XWELL entered into a strategic partnership with PieQ, an AI and predictive intelligence company, to develop a novel U.S. biosecurity...

TULSA, Okla., April 01, 2026 (GLOBE NEWSWIRE) — ONEOK, Inc. (NYSE: OKE) will release first-quarter 2026 earnings after the market closes on April 28, 2026. Members of ONEOK’s management team will participate in a conference call the following day. What:               ONEOK first-quarter 2026 earnings conference call and webcast When:              April 29, 2026, at 11 a.m. Eastern (10 a.m. Central) Where:            1) Conference call: Dial 800-343-5172 and use conference ID: OKE1Q26                         2) Webcast: Join at www.oneok.com If you are unable to participate in the conference call or the webcast, a recording will be available at www.oneok.com for one year. ——————————————————————————————————————————————————————————————– At...